The novelty of our study is the demonstration that modulation of GluN2B-NMDAR activity by its partial blockade has a potential to prevent Aβ—mediated synaptotoxicity and AICD-induced hypoexcitability, and restore synaptic plasticity in early AD. The gene discussed is GRIN2B; the disease is Alzheimer disease.